Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period

The study aims to (1) identify the botulinum toxin (BTX) dosing trend in a cohort of patients who received at least 20 injections for the treatment of adductor spasmodic dysphonia (ADSD), (2) describe two distinct BTX dosing trends in treating ADSD (a "classic" dosing trend that initially decreases before stabilizing, and a "fluctuating" dosing trend), and (3) determine if patients with the "classic" dosing trend differed in age or in dosing intervals from those with the "fluctuating" dosing trend.

from Speech via a.lsfakia on Inoreader http://ift.tt/1RsBD5c
via IFTTT